Optimizing Gastroenterology Prior Authorizations with Change Healthcare Clearinghouse

Klivira provides a robust solution for gastroenterology change healthcare clearinghouse workflows, automating the complex prior authorization process for high-volume GI treatments and procedures.

Gastroenterology practices face a significant prior authorization burden, particularly with biologics for IBD, advanced imaging, and endoscopic procedures. Integrating with a national clearinghouse like Change Healthcare is crucial for eligibility verification and claims submission, yet the PA process itself often remains a manual bottleneck. Klivira bridges this gap, transforming how GI practices manage authorizations within their existing revenue cycle infrastructure.

The Intersection of GI Prior Auth and Clearinghouse Operations

For gastroenterology, the efficient exchange of data via a clearinghouse like Change Healthcare is foundational for revenue cycle management, handling HIPAA X12 270/271 for eligibility checks and X12 837 for claims. However, prior authorization (PA) often involves clinical data not directly transmitted through standard clearinghouse transactions like X12 278. Klivira enhances this by automating the clinical submission and tracking, ensuring that detailed GI-specific documentation aligns with payer requirements, while still leveraging clearinghouse data for administrative efficiency.

High-Volume GI PA Triggers and Documentation Needs

Gastroenterology prior authorizations are heavily concentrated in specific, high-cost categories. Klivira's platform is engineered to manage these nuanced requirements, integrating clinical guidelines from bodies like ACG, AGA, and AASLD directly into the PA workflow. This ensures that submissions are evidence-based and complete, reducing the likelihood of denials.

Key Prior Authorization Categories in Gastroenterology

**IBD Biologics:** Including Humira, Stelara, Skyrizi, Entyvio, and other specialty IBD drugs, often requiring step therapy and disease severity documentation (e.g., Mayo score for UC, CDAI for Crohn's).
**Hepatitis C Direct-Acting Antivirals:** Such as Epclusa and Mavyret, with pathways differing based on genotype, fibrosis stage, and prior treatment history.
**Advanced Imaging:** MRCP, MR enterography, CT enterography for IBD assessment, requiring clinical justification and prior workup details.
**Endoscopic Procedures:** Capsule endoscopy (CPT 91110), small-bowel enteroscopy, ERCP, and EUS for specific diagnostic or therapeutic indications.
**Specialty Drugs for Functional GI Disorders:** Like Viberzi, Motegri, Linzess, and Trulance, often requiring documentation of diagnosis criteria (e.g., Rome criteria for IBS) and prior conservative therapy trials.

Klivira's Automated Approach to GI PA with Clearinghouse Integration

Klivira integrates seamlessly with your EMR to extract necessary clinical data, then intelligently routes prior authorization requests through appropriate payer channels (ePA, payer portals, X12 278 where supported). For gastroenterology, this includes ACG/AGA-guideline-aware step therapy logic for IBD biologics, automated treatment-status classification from EMR medication history, and specialized workflows for Hep C DAA documentation. Our platform complements Change Healthcare's role by automating the complex clinical submission, reducing manual effort and improving turnaround times.

Mitigating Common GI Prior Authorization Denials

Many GI PA denials stem from insufficient documentation or non-compliance with step therapy protocols. Klivira's system proactively identifies and flags missing information, such as disease severity scores, TB/hepatitis screening pre-biologic, or fibrosis stage for Hep C DAAs. By ensuring comprehensive, guideline-compliant submissions, Klivira helps gastroenterology practices reduce common denial reasons like biosimilar substitution requirements or inadequate prior workup for imaging and procedures.

Optimizing the Full Revenue Cycle for Gastroenterology

Beyond PA submission, Klivira's platform provides continuous re-authorization workflow for chronic IBD treatments and manages the medical-vs-pharmacy benefit split for biologics. By integrating with your EMR and leveraging the administrative data flow from clearinghouses like Change Healthcare, Klivira ensures that prior authorization is no longer a bottleneck but an integrated, automated component of the gastroenterology revenue cycle, from eligibility verification (X12 270/271) to final claims processing (X12 837).

Frequently asked questions

How does Klivira specifically address IBD biologic prior authorizations for gastroenterology?

Klivira incorporates ACG/AGA-guideline-aware step therapy logic to ensure correct sequencing of IBD biologics. It automates the extraction of disease severity scores (e.g., Mayo score, CDAI) and prior conventional therapy trials from the EMR, streamlining the submission of comprehensive clinical documentation required by payers for agents like Humira, Stelara, and Entyvio.

Can Klivira integrate with my existing Change Healthcare Clearinghouse setup?

Yes, Klivira is designed to integrate with your existing EMR and can leverage the administrative data flowing through clearinghouses like Change Healthcare. While Change Healthcare handles eligibility (X12 270/271) and claims (X12 837), Klivira focuses on automating the clinical prior authorization submission and tracking (ePA, payer portals, X12 278 where applicable), complementing your current revenue cycle infrastructure.

What role does Klivira play in managing the medical vs. pharmacy benefit split for GI biologics?

Klivira's platform is equipped to manage the complexities of biologic agents that may fall under either medical or pharmacy benefits depending on the administration mode. It helps route the PA request appropriately based on whether the agent is provider-administered (medical benefit) or self-administered (pharmacy benefit), ensuring compliance with payer-specific requirements.

How does Klivira handle the re-authorization burden for chronic GI conditions?

For chronic conditions like IBD requiring ongoing biologic therapy, Klivira automates the periodic re-authorization workflow. It tracks upcoming re-authorization dates, prompts for necessary updated clinical documentation (e.g., disease response), and facilitates timely submission to ensure continuity of care and prevent treatment gaps due to lapsed authorizations.

Does Klivira assist with prior authorizations for advanced GI imaging and endoscopic procedures?

Yes, Klivira supports prior authorizations for advanced GI imaging like MR enterography and specific endoscopic procedures such as capsule endoscopy (CPT 91110) or ERCP. The platform helps compile the required clinical justification, prior imaging history, and conservative-evaluation workup documentation to meet payer medical necessity criteria, reducing denials related to inappropriate-use criteria.